STOCK TITAN
  1. Home
  2. News
  3. CERT

Certara to Report Fourth Quarter and Full Year 2020 Preliminary Financial Results on March 4, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release preliminary financial results for the fourth quarter and full year of 2020 after the market close on Thursday, March 4, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (833) 360-0946 for domestic callers or (914) 987-7661 for international callers, followed by Conference ID: 6546156. A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.

About Certara

Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Stock CERT logo
Certara, Inc.

NASDAQ:CERT

CERT Rankings

#1703 Ranked by Market Cap
#1974 Ranked by Stock Gains
N/A Ranked by Dividends

CERT Latest News

May 7, 2024
Certara Reports First Quarter 2024 Financial Results
Apr 16, 2024
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
Apr 9, 2024
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
Feb 29, 2024
Certara Reports Fourth Quarter 2023 Financial Results
Feb 1, 2024
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference

CERT Stock Data

2.65B
109.07M
2.92%
97.79%
3.55%
Software Publishers
Information
Link
United States of America
PRINCETON

About CERT

certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. certara’s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies. for more information, visit www.certara.com.